Dare Bioscience, Inc.DAREEarnings & Financial Report
Nasdaq
NextMar 31, 2026
DARE Q3 2025 Key Financial Metrics
Revenue
$2.3K
Gross Profit
N/A
Operating Profit
$-3.7M
Net Profit
$-3.6M
Gross Margin
N/A
Operating Margin
-162340.8%
Net Margin
-157505.1%
YoY Growth
-94.6%
EPS
$-0.28
Financial Flow
Dare Bioscience, Inc. Q3 2025 Financial Summary
Dare Bioscience, Inc. reported revenue of $2.3K for Q3 2025, with a net profit of $-3.6M (-157505.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $2.3K |
|---|---|
| Net Profit | $-3.6M |
| Gross Margin | N/A |
| Operating Margin | -162340.8% |
| Report Period | Q3 2025 |
Dare Bioscience, Inc. Annual Revenue by Year
Dare Bioscience, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $9.8K).
| Year | Annual Revenue |
|---|---|
| 2024 | $9.8K |
| 2023 | $2.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $9302 | $22438 | $41691 | $-63647 | $25427 | $-21172 | $2262 |
| YoY Growth | N/A | N/A | N/A | -95.8% | -103.5% | 173.3% | -194.4% | -94.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $21.3M | $13.0M | $23.6M | $18.1M | $22.1M | $18.6M | $13.0M | $30.7M |
| Liabilities | $26.3M | $24.0M | $20.9M | $19.5M | $28.1M | $28.2M | $25.7M | $27.9M |
| Equity | $-5.0M | $-11.0M | $2.7M | $-1.5M | $-6.0M | $-9.6M | $-12.7M | $2.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.2M | $-6.8M | $12.9M | $-5.9M | $5.2M | $-5.5M | $-5.4M | $-442135 |